Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study

Annals of Hematology
Vu H DuongAref Al-Kali

Abstract

Acute leukemias of ambiguous lineage (ALAL) are rare hematologic malignancies with poor outcomes. Retrospective studies have suggested that acute lymphoblastic leukemia (ALL) regimens are more effective than acute myeloid leukemia (AML) regimens. We retrospectively examined the effectiveness of the widely-used adult ALL regimen hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyperCVAD) as initial therapy in patients with ALAL at five academic institutions. Twenty-five patients were identified, including 23 with mixed phenotype acute leukemia (MPAL) and two with acute undifferentiated leukemia. Five of 8 tested (63%) had FLT3-ITD and 3 of 25 (12%) were Philadelphia chromosome-positive. The complete remission (CR) rate was 76%, with CR with incomplete count recovery (CRi) in an additional 8%, for an overall response rate of 84%. Median number of cycles to CR/CRi was 1. There were no deaths in the first 30 days. Of the 21 patients achieving CR or CRi, 14 (66%) proceeded to allogeneic hematopoietic stem cell transplantation. With a median follow-up time of 31.6 months, median overall survival for the entire cohort was not reached, and the estimated 2-year survival was 63%. HyperCVAD can be considere...Continue Reading

References

Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianE J Freireich
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolas BoisselAndré Baruchel
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Aug 29, 2009·Haematologica·Amal S Al-SeraihyAsim F Belgaumi
May 21, 2010·Leukemia·W van den AnckerA A van de Loosdrecht
Nov 19, 2011·Hematology/oncology Clinics of North America·David P Steensma
Feb 16, 2013·Annals of Hematology·Sandra HeeschClaudia D Baldus
Oct 23, 2013·Annals of Hematology·Marcela Deffis-CourtErick Crespo-Solís
Jan 22, 2015·Blood·Ofir Wolach, Richard M Stone
Jan 22, 2015·European Journal of Haematology·Hiroaki ShimizuUNKNOWN Kanto Study Group for Cell Therapy (KSGCT)
Feb 24, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Reinhold MunkerUNKNOWN Center for International Blood and Marrow Transplant Research
Jan 19, 2017·Current Opinion in Hematology·Ofir Wolach, Richard M Stone
Oct 30, 2019·Cancer·Etan OrgelUNKNOWN Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.